The previous research work in the literature for capacity planning and scheduling of biopharmaceutical manufacture focused mostly on the use of mixed integer linear programming (MILP). This paper presents fast genetic algorithm (GA) approaches for solving discrete-time MILP problems of capacity planning and scheduling in the biopharmaceutical industry. The proposed approach is validated on two case studies from the literature and compared with MILP models. In case study 1, a medium-term capacity planning problem of a single-site, multi-suite, multi-product biopharmaceutical manufacture is presented. The GA is shown to achieve the global optimum on average 3.6 times faster than a MILP model. In case study 2, a larger long-term planning problem of multi-site, multi-product bio-manufacture is solved. Using the rolling horizon strategy, the GA is demonstrated to achieve near-optimal solutions (1% away from the global optimum) as fast as a MILP model.
Introduction
Biopharmaceutical drug development requires substantial investments of capital, human resources, and technological expertise. The cost of development of a single drug entering human trials between 1989 and 2002 was estimated to be in excess of $800M ( DiMasi et al., 2003 ) . The development costs have been rising substantially for years. In an analysis by Paul et al. (2010) , the cost of a new molecular entity was reported to be $1.8B. The likelihood of a new biopharmaceutical drug product gaining approval for marketing and the rate of approval for new products has been getting lower over the years. According to Kaitin and DiMasi (2010) , only one in six new drugs that entered clinical trials in the United States during 1993-98 and the 1999-2004 sub-periods were successfully approved for marketing. Shanley (2014) reported that only 12% of the candidate drugs get approved for use. Given the high costs and the uncertainty of the biopharmaceutical development process, building new capacity for products which may or may not reach the market is not the most desirable option. Therefore, it is essential to optimise the manufacturing capac-ity in an existing multi-product facility or a network of facilities. Ransohoff (2004) suggested that a typical mammalian cell-culture facility could increase annual revenues by $380M with a 25% increase in plant utilisation.
Biopharmaceutical production planning is a complex combinatorial optimisation problem complicated by the unique features of biomanufacture. Biopharmaceutical companies typically have a portfolio of various products manufactured across a network of owned and contract manufacturing facilities with wide-ranging production capabilities. Biopharmaceutical products tend to be unstable and thus have specialised and costly transportation and storage requirements. Biopharmaceutical companies are also required to meet high-quality standards and prove they can deliver a consistent manufacturing process. The high-quality standards are achieved by rigorous cleaning and sterilisation between individual production campaigns.
The research work in the literature for capacity planning and scheduling of biopharmaceutical manufacture has focused on discrete-time MILP formulations adapted from the pharmaceutical and chemical engineering industries ( Papageorgiou et al., 2001 ). The first medium-term capacity planning model for a multiproduct, multi-suite biopharmaceutical facility was presented by Lakhdar et al. (2005) . Their approach helped to determine the optimal durations and sequence of production campaigns together Integer variables product it part of the chromosome containing product labels allocated at time period t to USP suite i product jt part of the chromosome containing product labels allocated at time period t to DSP suite j time it part of the chromosome containing the number of production days allocated at time period t to USP suite i time jt part of the chromosome containing the number of production days allocated at time period t to DSP with product inventory, sales, and late deliveries profiles. Furthermore, the proposed MILP based optimisation method was shown to find more optimal solutions than the industrial rule-based approach.
The randomness of the biopharmaceutical manufacturing environment can cause significant scheduling and planning difficulties for the biopharmaceutical manufacturing campaigns. To address this, Lakhdar and Papageorgiou (2006) applied MILP and two-stage programming for medium-term planning of biopharmaceutical manufacture under uncertain fermentation titres. The proposed methodology achieved better results than the deterministic MILP model.
The optimisation of biopharmaceutical manufacturing capacity often involves many multiple conflicting criteria and objectives to be considered. George et al. (2007) presented a multi-criteria decision framework for the selection of strategies for acquiring biopharmaceutical manufacturing capacity. Lakhdar et al. (2007) addressed the challenge of making long-term, multi-site capacity planning decisions given multiple strategic criteria such as risk, cost, and customer service levels. Using goal programming, they developed a mathematical model that could optimise multiple objectives.
The vast part of the research on biopharmaceutical manufacture planning has been limited to either batch or fed-batch processes. However, a more recent, large-scale discrete-time MILP model was presented by Siganporia et al. (2014) to optimise long-term capacity plans for a portfolio of biopharmaceutical products, with either batch or perfusion bioprocesses, across multiple facilities to meet quarterly demands.
Genetic algorithms are stochastic, population-based search algorithms that follow the naïve laws of evolution and natural selection. Unlike most other conventional optimisation algorithms, GAs start from a pool of usually randomly generated solutions (also known as chromosomes). Chromosomes with a higher objective function value are selected for reproduction (crossover and mutation) to generate new and hopefully better solutions for each new iteration of the algorithm (also known as a generation). Since a population of solutions is processed in each iteration of the GA, the outcome is also a population of solutions. If an optimisation problem has a global optimum, then all chromosomes can be expected to converge to it. Alternatively, if an optimisation problem has multiple optimal solutions, GAs can capture them in its final population ( Deb, 2001 ) . Unlike classical optimisation methods which make assumptions about the relationships between the variables, constraints, and the objective, GAs are flexible optimisers making minimal assumptions about the problem. Therefore, despite the lack of guarantee of finding global optimum and the difficulty of designing the objective function, chromosome structure, and operators, GAs have been used to obtain approximate solutions to a wide range of complex linear and non-linear problem such as training neural networks ( Chen and Liao, 1998 ) , finding the optimal number, types, and positions of wireless transmitters ( Ting et al., 2009 ) , and creating a program capable of solving planning problems described in Planning Domain Definition Language (PDDL) ( Brie and Morignot, 2005 ) .
At the time of writing, the literature on the use of alternative optimisation methods such as genetic algorithms (GAs) in the biopharmaceutical industry was somewhat limited. Most of the publications focused on the management of product portfolios and the optimisation of process design. On the portfolio management front, George and Farid (2008) developed a stochastic, multiobjective optimisation framework based on probabilistic, modelbuilding genetic algorithms for the optimisation of the structure and development pathway of biopharmaceutical drug portfolios. Nie et al. (2012) presented a stochastic, GA-based decision-support tool to address the decisions involved in portfolio management at both the drug development process level and the portfolio level. On the process design front, Simaria et al. (2012) proposed a multiobjective GA-based approach for the selection and optimisation of purification sequences and chromatography column sizing strategies. Allmendinger et al. (2012) presented a GA for the discovery of chromatography equipment sizing strategies for antibody purification processes under uncertainty.
The performance of the GA depends on its hyperparameter values. For example, the rate of crossover controls the capability of the GA in exploiting the known parts of the search space, whereas the mutation rate controls the speed of the GA in exploring of new areas ( Lin et al., 2003 ) . The values of these parameters are quite often tuned one by one, i.e. by trial and error. However, this can be a time consuming process leading to suboptimal results, since the interactions between the parameters are ignored this way ( Eiben et al., 1999 ) . There has been a number of suggestions and theoretical investigations into the optimal values of crossover, mutation, and population size ( Back, 1993; Chipperfield and Fleming, 1995; Goldberg and Deb, 1991; Schaffer and Morishima, 1987 ) . The typical values of crossover and mutation rate have been reported to lie in the range 0.5-1.0 and 0.001-0.05 respectively. However, most investigations were based on simple function optimisation problems with traditional chromosome encoding strategies and genetic operators. Therefore, their applicability for other types of problems and custom genetic operators is quite limited. An alternative to manual parameter tuning is meta-optimisation, i.e. the use of another optimisation algorithm to tune the GA hyperparameters. For example, Grefenstette (1986) applied a meta-GA to optimise the hyperparameters of another GA. In this work, we use a particle swarm optimisation (PSO) algorithm to tune the GA. PSO is an evolutionary, stochastic optimisation technique modelled after swarming and flocking behaviours in animals, developed by James Kennedy and Russel Eberhart in the mid-1990s ( James and Russell, 1995; Luke, 2013 ) . PSO is similar to a GA since it is also a population-based algorithm. However, in PSO every solution is also assigned a randomised velocity vector and the potential solutions are called particles. A more detailed description of PSO algorithm can be found in an overview by Poli et al. (2007) . A PSO algorithm was chosen due to its simplicity and relatively low computational overhead (compared to using another GA) ( Pandey et al., 2010 ) and suitability for the optimisation of functions with continuous inputs ( Hassan et al., 2004 ) . This paper presents a fast GA-based approach to both mediumand long-term capacity planning and scheduling of singleand multi-site biopharmaceutical manufacture using discrete-time models. The proposed GA is demonstrated as a valid alternative to MILP to obtain near-exact solutions to close to real-world in- dustrial case studies of capacity planning and scheduling of biopharmaceutical manufacture. Other contributions of this paper include the chromosome encoding strategy, the algorithms describing the multi-suite and multi-site biopharmaceutical manufacture, the rolling horizon approach for solving larger, long-term capacity planning problems, and a PSO-based meta-optimisation approach for tuning the GA hyperparameters. The details of the proposed approach and two case studies are outlined in Section 2 of this paper. Section 3 is dedicated to the discussion of the results and the comparison between the GA and MILP. Conclusions and future work are provided in Section 4.
Methods
In this section, the case studies of capacity planning and scheduling of biopharmaceutical manufacture from two different literature sources are described. In case study 1, a medium-term capacity planning and scheduling problem of a multi-suite, multi-product biopharmaceutical manufacture from Lakhdar et al. (2005) is presented. In case study 2, a long-term capacity planning and scheduling problem of multi-site, multiproduct bio-manufacture from Lakhdar et al. (2007) is solved. The mathematical models are summarised in the Appendix; however, the reader is advised to refer to the original papers for a more indepth explanation.
In this paper, the MILP models were recreated in GAMS 23.9.5 and solved with a CPLEX 12.4.0.1 solver. GA and PSO algorithms were implemented using C ++ programming language. The implementation of mathematical models using algebraic modelling systems such as GAMS is entirely different compared to the generalpurpose programming languages. GAMS allows the mathematical models to be implemented in a way that is very similar to their mathematical description, while the general-purpose programming languages require an explicit definition of every expression. Another critical challenge of developing an efficient GA-based approach was identifying the smallest number of independent variables and the shortest sequence of steps needed to evaluate the candidate solutions for the case studies.
In this section, the structure of the proposed approach and the steps of the algorithms that captured capacity planning objectives for multiple products across multiple suites and facilities are outlined. Most of the proposed GA-based approach is detailed in the methods section for case study 1. In case study 2, the focus is placed on the rolling horizon strategy taken to improve the performance of the standard GA for solving the long-term capacity planning problem. The relative complexity of the optimisation problems is illustrated by the summary of the MILP model statistics shown in Table 1 . Both case studies were performed on an Intel i5-6500 based system with 16GB of RAM.
The process of identifying the optimal parameters for an optimization algorithm or a machine learning one is usually costly involves the search of a large, possibly infinite, space of candidate parameter sets, and may not guarantee optimality ( Camilleri et al., 2014 ) . In this work, a simple PSO algorithm is implemented as a meta-optimiser to automatically tune the crossover and mutation parameter values in both case studies. Each particle, i.e. a potential
Meta-Optimisation Algorithm (Particle Swarm Optimisation)
Meta-Optimisation Problem (find optimal GA crossover and mutation values)
Genetic Algorithm
Capacity Planning Problem (e.g. maximise operating profit) 
Table 2
Meta-optimisation parameters used in case study 1 and 2 to find the GA optimal crossover and mutation parameter values. solution, is initiated with randomised position and velocity vectors. A position vector holds the parameter values for the crossover and mutation. The fitness of each particle is assessed by running the GA using the parameter values from the position vector for a specified number of independent algorithm runs with fixed population size and measuring the average of the best objective function values achieved. The concept of the meta-optimisation is illustrated in Fig. 1 . The parameter values of PSO algorithm ( Table 2 ) were chosen based on the studies performed by Eberhart and Shi (20 0 0) and Trelea (20 03) .
Case study 1 -Medium-term capacity planning of a multi-suite, multi-product biopharmaceutical facility
The objective of the planning problem presented here is to generate a yearlong production schedule that would maximise the manufacturing profits. The problem statement adapted from Lakhdar et al. (2005) is as follows:
• Given:
• Biopharmaceutical products P = {p1, p2, p3}
• USP suites I = {i1, i2} and DSP suites J = {j1, j2}
• A planning horizon of 360 days made of equal time periods T = {t1, t2, …, t6} • Product-dependent production rates, lead times, and production throughputs (correspondence factors) • USP and DSP product shelf-life, storage capacities and costs • Product demands, sales price and backlog penalty costs • Manufacturing and campaign changeover costs • Minimum and maximum campaign durations t 1 t 2 t 3 t 4 t 5 t 6 … t n USP suites
Chromosome encoding strategy for case study 1. Each "(p, CT ipt ) " pair represents a gene with the information regarding which product p and how many days CT ipt have been allocated to each USP suite i at a time period t.
• Determine:
• Duration and sequence of campaigns • Production quantities along with inventory profiles • Product sales and late deliveries profile • To:
• Maximise manufacturing profits 2.1.1. Chromosome structure In both case study 1 and case study 2, the chromosomes use the direct encoding of the key variables from the mathematical models. Compared to the traditional form of binary encoding, e.g. Holland (1975) , real-coded GAs have been shown to be more consistent from run to run and provide faster, more precise performance ( Gaffney et al., 2010; Janikow and Michalewicz, 1991 ) . In case study 1, each chromosome is an |I|-by-|T| array of tuples where I is a set of USP suites, and T represents a set of discretetime periods (illustrated in Fig. 2 ) . Each tuple comprises a product label p and the length of production in USP suite i at time period t, CT ipt , measured in days both of which are randomly generated at the beginning of the GA.
Genetic algorithm
The GA comprises the following critical steps: fitness evaluation, tournament selection, reproduction (i.e. crossover and mutation), and replacement. In case study 1, chromosomes for crossover and mutation are selected using a binary tournament with replacement strategy which favours individuals with a higher objective function value, i.e. schedules with a larger profit value. Tournament selection has been shown to be computationally more efficient and have better or equivalent convergence when compared to other selection methods that are available in the literature ( Goldberg and Deb, 1991; Melanie, 1996 ) . A uniform crossover operator with a probability pC ( Table 3 ) is used to exchange the tuples between the chromosomes. Each tuple is also mutated with a small probability pM ( Table 3 ) to avoid premature convergence and improve the quality of the final solution. During mutation, the product label is changed by replacing it with a random value from the set of available products P. The length of production is varied by adding or subtracting a random number of days, ensuring the allocated campaign time is within the constrained range, CT min ip and CT max ip . In both case studies, the GA is augmented with elitism which is a highly exploitative method of preserving the fittest chromosomes from the previous population ( Luke, 2013 ) . In case study 1, a single best chromosome is re-inserted into the population whenever it is lost. Finally, the GA is set to terminate early if the fitness of the best individual has not improved for 100 consecutive generations.
Fitness evaluation
The fitness evaluation procedures of case study 1 and case study 2 are adapted from the MILP models ( Lakhdar et al., 2007 ( Lakhdar et al., , 2005 of multi-product biopharmaceutical manufacture. In case study 1, the fitness evaluation procedure generates a complete production schedule which is used to estimate the objective function value, i.e. profit. The pseudo algorithm of the fitness evaluation procedure for case study 1 is presented in Table 4 . d Average of best objective function values from 100 independent GA runs (mean ± 1 standard deviation).
e The parameter values were selected using the PSO algorithm.
f If the best objective function value remained the same for 100 consecutive generations, the GA was terminated.
In Table 4 , Lines 3 and 4 retrieve the product label p and the number of production days allocated to USP suite i at time period t, CT ipt , from the chromosome which is an |I|-by-|T| array where I is a set of upstream suites and T is a set of time periods. Lines 5 and 6 calculate the number of changeovers and batches produced in USP suite i at time period t . In Line 5, the value of the changeover variable Z ipt will be equal to 1 only if product p has not been produced in USP suite i at a previous time period t -1. Line 7 accumulates the production from all USP suites. Lines 9 and 10 estimate the amount of product p wasted in USP suites at time period t which is equal to the number of batches that was left unprocessed from ζ p periods ago. The amount of USP inventory of product p at time period t is calculated in Line 11 by adding the cumulative value obtained in Line 7 from time period t -1 and subtracting the amount of waste, CW pt .
Line 13 ensures that the assignment of product p to DSP suite j at time period t is performed only once. Lines 14 and 15 assign product p to DSP suite j and calculate how many batches will be produced in that suite at time period t . This is performed by multiplying the USP inventory value CI pt by the production correspondence factor λ p which specifies the respective throughputs from USP and DSP suites. For example, a factor of 0.5 signifies that for every two USP batches one DSP batch is produced. Line 15 evaluates the number of changeovers in DSP suites similarly to Line 7. Line 16 checks whether the length of production of product p in DSP suite j at time period t does not exceed the allowed maximum. If it does, the value of variable B jpt is iteratively decremented until the production time FT jpt is below or equal the value of the constraint, F T max p . Line 17 updates the value of USP inventory of product p at time period t by subtracting the number of batches that The fitness of each chromosome is assessed by calculating the profit achieved by the schedule using the same objective function (1) as presented by Lakhdar et al. (2005) . The objective function value is equal to the difference between the total sales and the costs of manufacturing, product changeovers, intermediate and final product storage, waste disposal, and late deliveries.
P ro f it
= p t ν p S pt − i η p B ipt − i ψ p Z ipt − j η p B jpt − j ψ p Z jpt −ρ p CI pt −ω p F I pt −δ p pt −τ p CW pt + F W pt(1)
Case study 2 -Long-term capacity planning and scheduling problem of multi-site, multi-product bio-manufacture
The goal of the planning problem presented in this case study is to generate a 15-yearlong production schedule to maximise manufacturing profits. The problems presented here is a single-objective problem adapted from Lakhdar et al. (2007) . The following is a problem statement:
• A network of multi-product facilities I = {i1, i2, …, i15}
• A planning horizon of 15 years with equal time periods T = {t1, t2, …, t60} • Production rates, yields, and lead times • Product lifetimes and storage capacities • Product demands and sales prices • Backlog decay factor • Manufacturing, changeover, storage costs, and late delivery penalties • Minimum and maximum campaign durations • Determine:
• Campaign durations and sequence of campaigns • Production quantities along with inventory profiles • Product sales and late deliveries profile • To:
• Maximise manufacturing profits
In their paper, Lakhdar et al. (2007) stated that the presented MILP model was an extension of the one already discussed in case study 1 of this paper. The core mathematical formulation for the single-objective problem remained mostly the same with the only most noticeable change being the lack of the explicit model of separate USP and DSP suites. Nevertheless, the complexity of the problem in case study 2 is much higher compared to case study 1 due to a greater number of products, facilities, and time periods. Each individual time period t is limited to a maximum of 87 days compared to 60 in case study 1, and there are 10 products which need to be allocated to 15 facilities. Additional subsets are introduced to define facility availability and manufacturing capability: PI i , the set of products that can be manufactured in facility i , and TI i , the set of time periods during which facility i is available for use. Furthermore, the production yield, as well as manufacturing costs of each product p, also depend on the facility i it is being manufactured in.
Chromosome structure
The increased complexity of the planning problem in case study 2 presented a challenge for the GA-based approach. Encoding the chromosomes as full-scale |I|-by-|T| arrays was found to be computationally costly. A rolling horizon method was taken to explore the large search space in a more efficient manner by dividing the 15-yearlong planning problem into 15 equal sub-problems which were solved consecutively. In order to accomplish this, each chromosome encoded a sub-problem as an |I|-by-|T| array of product p and the length of production, T ipt , values where T ⊂ T and |T| = 4. T represents the extent of the rolling horizon, i.e. a dynamic subset of 4 time periods which correspond to the timeline of the subproblem being solved. For example, T = {t1, t2, t3, t4} and T = {t57, t58, t59, t60} contain the time periods for the first and last subproblems, respectively. The best solution from each sub-problem is stored in the final, full-scale |I|-by-|T| solution, before proceeding to solve the following sub-problem. The values of the variables corresponding to the best solution such as the number of batches of product p produced in each facility i during time period t, B ipt , are fixed so they would not need to be recalculated for the next sub-problem. To distinguish the rolling horizon approach-based GA from the standard one, it will be referred to it as the dynamic GA. The concept of the dynamic GA is illustrated in Fig. 3 . The pseudoalgorithm for the dynamic GA is listed in Table 5 .
A new parent population is generated for every sub-problem with the values of product p for each facility i selected randomly from the set of allowable products for that facility, PI i , making sure the facility i is also available for use at time period t ∈ TI i . A product label with a value of 0 is also included in the set to denote an idle state of the facility i during a time period t when no product is being manufactured.
Genetic algorithm
A uniform crossover operator with a probability pC ( Table 6 ) is used to create two offspring from two parent chromosomes. T noise into the system, the mutation of the values of p and T is made independent, i.e. the probabilities pMutP and pMutT ( Table 6 ) associated with each step are independent of one another. Provided that the facility i is available for use at time period t , the value of product label p is mutated by assigning 0 or a random value from the subset PI i . The value of T ipt is mutated by adding or subtracting a random number of days, ensuring the allowable range for T ipt is not exceeded.
The parent population of gen + 1 is made up of the recombined and mutated offspring. If no better solutions are found, then the top 5% of the previous parent population replace the worst performers of the latest generation. A completely new parent population is generated when the best fitness value remains unchanged for a specified number of consecutive generations (Lines 14-16, Table 5 ) and the previous top 5% chromosomes are added. When e The parameter values were selected using the PSO algorithm.
f If the best objective function value remained unchanged for 25 consecutive generations, the GA was restarted with a new parent population. The second time the best objective function value stayed the same for the same number of generations, the GA was terminated.
g Terminated after 10 0 0 generations had elapsed irrespective of the best objective function value achieved. a Average of best objective function values from 50 independent GA runs (mean ± 1 standard deviation). b Max objective function value obtained from 50 independent GA runs. c If the best objective function value remains unchanged for a given number of consecutive generations, the GA is restarted with a new parent population. The second time the best objective function value stays the same for the same number of generations, the GA is terminated.
Table 8
Pseudocode for fitness evaluation in case study 2.
for each product p 25
this repeats, the best sub-problem is added to the full solution, and a new sub-problem is started (Lines 14, 17-20, Table 5 ). We tested terminating the GA after 25, 50, and 75 generations with population sizes of 100, 200, and 300 chromosomes ( Table 7 ) .
Fitness evaluation
In Table 8 , the variable ξ is used to iterate through the values of the |I|-by-|T| array contained within each chromosome . The product label p and production length T ipt are retrieved from the chromosomes in Lines 4 and 5 . The value of the binary changeover variable Z ipt is set to 1 in Line 6 if variable B ip,t -1 , the number of batches of product p produced in facility i in the previous time period slot, is 0. The value of the number of batches variable B ipt during time period t is calculated in Line 7 and converted into kilograms K ipt using the yield conversion factor yd ip in Line 8. The value of yd ip depends the facility i which the product p is being manufactured in. Line 9 accumulates the value of K ipt into the variable I pt -the amount of product p in kilograms stored at time period t. The amount of product waste W pt is estimated in Line 12 and 13. The value of this variable is equal to the amount of product p that was not sold and remained in storage for more than ζ p time periods. The rest of the pseudocode in Table 8 (from Line 14 and onwards) is nearly identical to the Lines 27-45 from the pseudocode for the fitness evaluation in case study 1 ( Table 3 ). The only notable differences are the lack of storage capacity constraint and the addition of backlog decay factor π which diminishes the importance of the backlogged orders during the fitness evaluation in case study 2.
The fitness of each chromosome is evaluated using the objective function of profit maximisation (2) defined by Lakhdar et al. (2007) . The objective function value is equal to the difference between the total sales, with each batch sold at a price ν p , and the total operating costs which include the costs of manufacturing, product changeovers, storage, and late deliveries.
Results and Discussion
In this section, the results to the case studies of capacity planning and scheduling of biomanufacture from the literature are presented. In case study 1, the problem consists of a multi-suite facility, with 2 USP ( I = {i 1 , i 2 } ) and 2 DSP ( J = {j 1 , j 2 } ) suites to produce 3 products ( P = {p 1 , p 2 , p 3 } ) with multiple intermediate demand dates due during a 360-day long production time horizon. The horizon is discretised into 6 time periods ( T = {t 1 , t 2 , …, t 6 } ) of 60 days. In case study 2, the problem consists of 10 facilities ( I = {i 1 , i 2 , …, i 10 } ) with different manufacturing capabilities PI i (subset of facilities capable of producing product p ) and availability TI i (subset of facilities available at time period t ) to produce 15 products ( P = {p 1 , p 2 , …, p 15 } ) due annually during a 15-yearlong production time horizon. The horizon consists of 60 discrete time periods ( T = {t 1 , t 2 , …, t 60 } ) of 87 days.
The GAs discussed in the previous sections for case study 1 and case study 2 are used to solve the respective scheduling problems, and the results are compared with the recreated MILP models (see Tables 3 and 6 ) . A comparison between the production schedules generated using MILP, and a GA is also provided in Figs. 4 and 5 . The reader is advised to refer to the original papers ( Lakhdar et al., 20 07, 20 05 ) for the input data used.
Case study 1 results
The proposed GA developed in this research was first applied to case study 1 on medium-term capacity planning for a singlesite, multi-suite, multi-product biopharmaceutical facility. Initially, a MILP model was developed for the problem as a benchmark for comparison with the GA performance. In their original MILP work, Lakhdar et al. (2005) reported an objective function value of 487 relative monetary units (RMU) with a 5% optimality gap for this problem, while using the reproduced MILP model an objective function value of 490 RMU was achieved with 0% optimality gap indicating a global optimum. Fig. 4 . Production schedule for case study 1 with an objective function value of 490 RMU and 0% optimality gap. Both the MILP model and the proposed GA generated the same schedule. The first number in each cell denotes the number of batches produced which is followed by the production time [days] in brackets. The shading of the box indicates which product is being manufactured.
The proposed PSO-based meta-optimisation approach was used to tune the crossover and mutation parameter values, pC and pM . Using this approach, the optimal values of crossover rate ( pC = 0.710 ) and mutation rate ( pM = 0.070 ) were identified, and the GA achieved the global optimum of 490 RMU for 100 consecutive, independent algorithm runs. The GA also generated a production schedule with the product allocation pattern identical to the one from the recreated MILP model ( Fig. 4 ) . The average solution time of the GA was 0.07 s compared to MILP which took an average of 0.22 s to find the global optimum (the MILP model was run 10 times to evaluate the running time).
Given the fast performance of the proposed GA-based method and the optimality of the results, it can be considered as a viable alternative for addressing medium-term capacity planning and scheduling problems similar in structure and complexity to case study 1.
Case study 2 results
Having tackled medium-term, single-site facility scheduling, the GA was then extended to address long-term planning across multisite, multi-product biopharmaceutical manufacturing facilities in case study 2. To set the benchmark for the GA, the recreated single-objective MILP model was used to achieve an objective function value of 66,360 RMU with a 0% optimality gap for this problem. It took approximately 16.7 min to find the global optimum. With the optimality gap increased to 1%, the MILP model achieved an objective function value of 65,940 RMU in 8.77 s.
As discussed earlier, two versions of a GA ( standard and dynamic ) were applied to solve the long-term capacity planning problem presented in case study 2. Using the standard version, each chromosome encoded the full-scale problem as an |I|-by-|T| array (where | I| = 10 and |T| = 60), and the GA was set to terminate after 10 0 0 generations had elapsed. In the dynamic version, a rolling horizon approach was utilised to break down the full-scale 15-yearlong scheduling problem into 15 sub-problems. Each chromosome encoded only a part of the full schedule as an |I|-by-|T| array (where T ∈ T and |T| = 4 ) corresponding to the sub-problem being solved. Additionally, the dynamic GA was restarted once the fitness value remained unchanged for a set number of consecutive generations. The crossover, mutation and elitism steps were identical in both standard and dynamic versions.
The comparison of the results between the MILP and GA is summarised in Table 6 . For a fair comparison, the PSO-based metaoptimisation was applied to tune both GA versions. After 50 runs, the average best objective function value using the standard GA was 61,186 ± 437 while the dynamic GA achieved 65,652 ± 112 . Additionally , the solution time of the dynamic GA was approximately 2.7 times faster than that of the standard version (8.09 s vs 21.56 s) and slightly faster than that of the relaxed MILP model (8.09 s vs . Production schedules for case study 2. Each product p n (where n = 1, 2, …, 15) is denoted by a colour label displayed in the legend below the schedules. The numbers of batches of each product produced have been removed for clarity purposes. A) Generated using the MILP model. An objective function value of 65,940 RMU was obtained with 0.6% optimality margin (based on the known global optimum as the upper bound). B) Generated using the dynamic GA. An objective function value of 65,849 RMU was obtained (0.8% estimated optimality margin).
s).
Using the known global optimum of 66,360 RMU as an upper bound, the average and the lowest optimality gaps achieved using the dynamic GA were estimated to be 1.0% and 0.8%, respectively. In comparison, the relaxed MILP model returned an objective function value of 65,940 with a 0.6% optimality gap
The pattern of the most profitable production schedule produced by the dynamic GA ( Fig. 5 B) holds a close resemblance to the MILP-generated one ( Fig. 5 A) , for example:
• Facilities i 1 and i 2 run with little to no idle time and with a variety of different products allocated to them.
• Facility i 3 is busier in the first half of the scheduling table with more product allocations.
• Product p 4 is almost exclusively produced in the facility i 4 .
• Facility i 4 has no idle time periods.
• Certain facilities such as i 5 and i 10 are completely idle.
Nevertheless, the production schedule generated with MILP is more systematic and has more products allocated overall. For example, in Fig. 5 A, the product allocation in the facility i 8 is more consistent than in Fig. 5 B, in which the production is scheduled as late as possible thus saving storage costs.
Conclusions
In this work, novel GA-based optimisation approaches were developed for medium and long-term, discrete-time, mixed-integer capacity planning models of biopharmaceutical manufacture. The key enabling features of the GA-based approaches included a chromosome encoding strategy, a dynamic, rolling horizon approach to improving the performance of the GA for tackling the long-term capacity planning and scheduling problem, and algorithms that captured capacity planning objectives for multiple products across multiple suites and facilities. A PSO-based metaoptimisation method was also presented for automatic tuning of crossover and mutation parameter values as an alternative to manual tuning. The feasibility of the novel GA-based optimisation algorithms was demonstrated on two case studies from the literature.
In case study 1, a medium-term capacity planning problem of a single-site, multi-suite biopharmaceutical facility was solved. The proposed GA obtained the global optimum with less CPU time than a MILP model.
In case study 2, a more computationally complex, long-term capacity planning problem of a multi-site biopharmaceutical manufacture was solved. Using the rolling horizon approach, the fullscale problem was divided into 15 sub-problems which were solved consecutively. Based on the known global optimum, the average optimality gap of the solution generated using the dynamic GA was 1.0%.
In this paper, the GA-based approaches were demonstrated to be capable of achieving the exact or very similar performance compared to MILP in terms of the objective function optimality and speed. This paper serves as a starting point for tackling even more complex capacity planning and scheduling problems of biopharmaceutical manufacture using GA-based approaches. In the future, the work presented in this paper could be extended to address stochastic planning problems with uncertain parameters, e.g. fermentation titres or product demand, as well as multi-objective problems. 
Storage constraints
Constraints 11 and 12 enforce an inventory balance in upstream and downstream production and force the total downstream production to meet the product demand. Constraints 13 and 14 ensure that the amount of upstream and downstream product stored over timer period t is positive and below the maximum available storage capacities, C p and F p . Both upstream and downstream product inventory is constrained by the limited product shelf-life. Constraints 15 and 16 ensure the total amount of stored upstream product and downstream product is used after the next ζ p or σ p time periods, respectively. 
Objective function
The objective function is to maximise profit which is equal to the difference between total sales and total operating costs. All costs and prices are in relative monetary units (RMU 
Appendix B
This appendix summarises the mathematical model presented by Lakhdar et al. (2007) .
Production constraints
Constraint 1 represents biopharmaceutical production. The number of batches produced in facility i of product p at time period t, B ipt , is represented by a continuous production rate, r ip , production lead time, α ip , and production time T ipt . Constraint 2 converts the integer number of batches , B ipt , into kilograms, K ipt , using a yield conversion factor , yd ip . Constraint 3 activates lead time in facility i if the same product p has not been manufactured in the preceding time period, t − 1. Constraint 4 ensures that only one product p is produced in any facility i at any time period t . 
Storage xonstraints
Constraint 7 enforces inventory balance for production and forces the total production to meet the product demand. Constraint 9 enforces that the amount of product p in inventory at time period t is below the maximum storage capacity, C p , while the constraint 10 ensures that the global storage capacity, C tot p , is not exceeded. The duration a product can be is stored in inventory is limited by the constraint 10. 
Objective function
